13 November 2017: PlaqueTec Announces the Appointment of Annalisa Jenkins, MBBS, FRCP, as Chief Executive Officer
The Board of Directors of PLAQUETEC LTD (‘PlaqueTec’) today announced the appointment of Annalisa Jenkins, MBBS, FRCP, as the company’s Chief Executive Officer. Dr. Jenkins, most recently CEO of US‐based Dimension Therapeutics, will lead the 2018 launch of the pioneering biomarker‐based PlaqueTec Liquid Biopsy SystemTM (LBS). The much anticipated LBS is designed to improve risk assessment and facilitate earlier intervention in the management of coronary artery disease (CAD), the leading cause of death worldwide.
18 November 2015: PlaqueTec announces the appointment of Dr Nick West as CMO
CAMBRIDGE, UK – PLAQUETEC LTD (‘PlaqueTec’), the Cambridge-based company pioneering the development of a biomarker-based approach to transform the understanding of coronary artery disease (CAD), the leading cause of death worldwide, announced today the appointment of Dr Nick West as Chief Medical Officer.
29 July 2014: PlaqueTec secures CE mark for its Liquid Biopsy System a breakthrough device for harvesting novel biological information from the diseased coronary artery
PlaqueTec has developed and patented the Liquid Biopsy System (LBS) for collecting biological data associated with heart disease directly from the coronary arteries. The LBS takes multiple blood samples concurrently from different locations within the coronary artery of patients and looks for elevations in biological activity in diseased segments. The LBS has the potential to drive the discovery and development of new drugs and therapeutics, as well as being able to evaluate the efficacy of both approved drugs and agents in development.